nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas
|
Agulnik, M. |
|
|
28 |
1 |
p. 121-127 |
artikel |
2 |
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab
|
Pierga, J.-Y. |
|
|
28 |
1 |
p. 103-109 |
artikel |
3 |
Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression
|
Takeshita, M. |
|
|
28 |
1 |
p. 186-189 |
artikel |
4 |
Common breast cancer risk alleles and risk assessment: a study on 35 441 individuals from the Danish general population
|
Näslund-Koch, C. |
|
|
28 |
1 |
p. 175-181 |
artikel |
5 |
Cyclin D mediates tolerance of genome-doubling in cancers with functional p53
|
Crockford, A. |
|
|
28 |
1 |
p. 149-156 |
artikel |
6 |
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives
|
Costa, R. |
|
|
28 |
1 |
p. 44-56 |
artikel |
7 |
Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?
|
Del Paggio, J.C. |
|
|
28 |
1 |
p. 157-162 |
artikel |
8 |
Editorial board
|
|
|
|
28 |
1 |
p. ii-iii |
artikel |
9 |
Erlotinib and acid suppressive agents: is it worth to take a coke?
|
Retamero, A. |
|
|
28 |
1 |
p. 192-193 |
artikel |
10 |
Fulminant type 1 diabetes caused by dual immune checkpoint blockade in metastatic renal cell carcinoma
|
Teló, G.H. |
|
|
28 |
1 |
p. 191-192 |
artikel |
11 |
‘Genotype/immunotype’ correlations in resected NSCLC
|
Paik, P.K. |
|
|
28 |
1 |
p. 7-8 |
artikel |
12 |
Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard
|
Powell, M.A. |
|
|
28 |
1 |
p. 9-10 |
artikel |
13 |
Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial
|
McDonald, J. |
|
|
28 |
1 |
p. 163-168 |
artikel |
14 |
Is the routine use of trimodality therapy for selected patients with non-small cell lung cancer supported by long-term clinical outcomes?
|
Dickhoff, C. |
|
|
28 |
1 |
p. 185 |
artikel |
15 |
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations
|
Iwama, E. |
|
|
28 |
1 |
p. 136-141 |
artikel |
16 |
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)
|
Yamasaki, M. |
|
|
28 |
1 |
p. 116-120 |
artikel |
17 |
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
|
Dieter, S.M. |
|
|
28 |
1 |
p. 142-148 |
artikel |
18 |
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function
|
Choi, M. |
|
|
28 |
1 |
p. 83-89 |
artikel |
19 |
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies
|
Salama, A.K.S. |
|
|
28 |
1 |
p. 57-74 |
artikel |
20 |
PARP inhibition in BRCA2-mutated prostate cancer
|
Nientiedt, C. |
|
|
28 |
1 |
p. 189-191 |
artikel |
21 |
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
|
Shi, W. |
|
|
28 |
1 |
p. 128-135 |
artikel |
22 |
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone
|
Massard, C. |
|
|
28 |
1 |
p. 90-95 |
artikel |
23 |
Practical guidance for mismatch repair-deficiency testing in endometrial cancer
|
Stelloo, E. |
|
|
28 |
1 |
p. 96-102 |
artikel |
24 |
Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?
|
Danesi, R. |
|
|
28 |
1 |
p. 183 |
artikel |
25 |
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
|
An, E. |
|
|
28 |
1 |
p. 110-115 |
artikel |
26 |
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|
Cardoso, F. |
|
|
28 |
1 |
p. 16-33 |
artikel |
27 |
Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
|
Deenen, M.J. |
|
|
28 |
1 |
p. 184 |
artikel |
28 |
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples
|
Renfro, L.A. |
|
|
28 |
1 |
p. 34-43 |
artikel |
29 |
Table of Contents
|
|
|
|
28 |
1 |
p. iv-vi |
artikel |
30 |
Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib—hype or me-too?
|
Mir, O. |
|
|
28 |
1 |
p. 13-15 |
artikel |
31 |
Thanks to referees 2016
|
|
|
|
28 |
1 |
p. 1-6 |
artikel |
32 |
The potential and perils of observational studies
|
Buyse, M. |
|
|
28 |
1 |
p. 182 |
artikel |
33 |
The search for simplicity: is this compatible with precision medicine?
|
Nuciforo, P.G. |
|
|
28 |
1 |
p. 10-12 |
artikel |
34 |
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
|
Husseini, F. |
|
|
28 |
1 |
p. 169-174 |
artikel |
35 |
Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
|
Kadara, H |
|
|
28 |
1 |
p. 75-82 |
artikel |